Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin (2024)

Peer-Reviewed Study · (J Cell Mol Med 2024; authors not captured in the retrieved record) · 2024

(J Cell Mol Med 2024, 2024: CML cell-line study establishing a flumatinib-resistant K562 subline that over-expresses P-glycoprotein, ABCC1 and ABCC4 and remains sensitive to ivermectin, which suppressed the resistant phenotype.

This cell line exhibited cross-resistance to imatinib and doxorubicin, but remained sensitive to the antiparasitic agent ivermectin, which possesses antitumoural effects.

(J Cell Mol Med 2024, 2024: CML cell-line study establishing a flumatinib-resistant K562 subline that over-expresses P-glycoprotein, ABCC1 and ABCC4 and remains sensitive to ivermectin, which suppressed the resistant phenotype. Study type: CML cell line K562 and derived flumatinib-resistant K562/FLM, in vitro. N: n/a. Country: China (Yuebei People's Hospital, Shantou University Medical College). Dose: not stated in the abstract. Declared COI: 'The authors confirm that there are no conflicts of interest.' Comparator: parental K562 cells and flumatinib alone. Supports the MDR-reversal claim by showing retained ivermectin sensitivity in a P-gp/ABCC-overexpressing resistant line. Study type: lab.